Abciximab

Active ingredient description

Abciximab is the Fab fragment of the chimeric monoclonal antibody 7E3. It is directed against the glycoprotein (GP) IIb/IIIa (αIIbβ3) receptor located on the surface of human platelets. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Abciximab
B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC13

Medicines

Abciximab is the active ingredient of these drugs:

Drug
Countries

Brazil

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)
UK

Unique ingredient identifier (UNII)

X85G7936GV - ABCIXIMAB

CAS registry number

143653-53-6 - abciximab

SNOMED-CT

386951001 - Abciximab (substance)